WuXi Biologics stock trades near its 52-week high after H1 growth

Published on 10/07/2026 at 07:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

WuXi Biologics stock posted H1 revenue growth of 23.4 percent in constant currency, with 2026 guidance raised to 20-23 percent. The October 7 price sits 1.98 percent below its yearly high.

WuXi Biologics, KYG970081173, Illustration mit AI erstellt.

WuXi Biologics stock (ISIN KYG970081173) was trading at HKD 56.85 on the Hong Kong Stock Exchange on October 7, 2026 at 11:59 a.m. HKT, 1.98 percent below its 52-week high of HKD 58.00. The market is weighing that strong chart position against the company's latest operating update, which showed H1 2026 revenue growth of 23.4 percent in constant currency.

H1 growth resets the benchmark

According to Investing.com, WuXi Biologics reported H1 2026 revenue growth of 23.4 percent in constant currency, the fastest pace in four years. Adjusted net profit rose 38.6 percent to RMB 3.9 billion, while adjusted gross margin expanded by 280 basis points to 48.4 percent.

The company also lifted its 2026 constant-currency revenue guidance to 20-23 percent from 16-20 percent, according to Investing.com. That upgrade gives the reported H1 growth a forward reference point, although the guidance is stated in constant-currency terms and should not be compared directly with an unadjusted revenue figure.

FDA inspection supports supply reliability

WuXi Biologics' Wuxi Mashan drug substance and drug product facilities passed an unannounced two-week FDA GMP inspection in September 2026, covering monoclonal antibodies, bispecific antibodies, fusion proteins and enzyme products, as Pharma Manufacturing reported on September 25, 2026.

The site has achieved a 100 percent success rate in more than 600 regulatory and client audits over 13 years and has supported the global launch of more than 20 biologics, the report said. The operational benefit is concrete: integrated drug substance and drug product capacity can reduce technology-transfer steps and support commercial supply for US-approved products.

Consensus target stays close

The consensus published by Investing.com covers 28 analysts, including 23 Buy ratings, 5 Hold ratings and 0 Sell ratings. The average 12-month price target is HKD 58.20, which lies 2.37 percent above the October 7 trading price of HKD 56.85.

That narrow gap makes execution more important than a simple valuation rerating. WuXi Biologics carried a market capitalization of HKD 235.6 billion and volume of 10,694,914 shares at the October 7 quote, while its 52-week range remained HKD 28.48 to HKD 58.00.

WuXi Biologics stock holds near yearly high

At HKD 56.85, WuXi Biologics stock was down 1.81 percent from the previous close during the October 7 Hong Kong session. The next test is whether the 20-23 percent guidance range and the FDA inspection record can support continued demand as the company expands complex biologics manufacturing.